Institut Mérieux Strengthens its Commitment to Medicine and Global Public Health

Paris (ots/PRNewswire) - Institut Mérieux strengthens
its commitment to medicine and global public health via an ambitious
innovation policy, the structuring of a food safety/nutrition hub and
the creation of a company dedicated to diagnostics in developing
countries.

One year after reinstating the historic name of Institut Mérieux
for the family holding devoted to industrial biology, Alain Mérieux
and the management teams of the companies, bioMérieux, Transgene,
Mérieux Nutrisciences and Mérieux Développement, have presented the
actions implemented within the scope of their innovation and
international development strategy with:

- the structuring of a food safety/nutrition hub based around Mérieux
NutriSciences, completing and supporting the diagnostic and therapeutic
Areas covered by Institut Mérieux
- the Group's innovation policy with, in particular, the first holdings
by its investment company, Mérieux Développement
- the development of biology accessible to all with the creation of
IMAccess, a not-for-profit company devoted to diagnostics in developing
countries.

"Institut Mérieux has undergone considerable changes to address
the new global challenges in medicine and public health. The arrival
of Jean-Luc Bélingard as Président Directeur Général of bioMérieux
and Vice-President of Institut Mérieux will enable me to devote more
time to Institut Mérieux and the Mérieux foundations", stated Alain
Mérieux. "Now, more than ever, scientific innovation,
multidisciplinary approaches and international development are at the
heart of our strategy. In an ever-changing healthcare environment,
with infectious disease representing a constant threat, the emergence
of new risks associated with food and now better known interactions
between infectious diseases, cancers and nutrition, we have made sure
we have new resources to achieve our long-term targets. The
structuring of a nutrition/health hub, which is highly complementary
to our therapeutic and diagnostic activities, is a strong example.
Our innovation strategy is also taking form with Mérieux
Développement and a stronger international network of scientific
experts. Finally, IMAccess aims to offer a complementary approach to
conventional models, to make quality biology and diagnostics
accessible to the greatest number and thus combat infectious
diseases, with no borders between North and South."

Institut Mérieux prioritizes nutrition

Institut Mérieux is increasing its commitment in the area of food
safety and nutrition by structuring a food safety/nutrition hub based
around Mérieux NutriSciences. With Silliker, its very first company
in the field of food safety, Biofortis and Bioagri, Mérieux
Nutrisciences is now developing an end-to-end offering to meet the
needs of players in the food processing chain: raw material and
environmental safety and conformity, food quality, R&D and clinical
trial program in the area of nutrition to help develop foods offering
a health benefit.

The originality and strength of the Mérieux NutriSciences
approach lie in the combination of Silliker's know-how in the food
sector with Institut Mérieux's scientific expertise and international
network, making it possible to include a medical vision and a public
health dimension in all its activities.

With its financial structure strengthened by an increase in the
subscribed capital by Institut Mérieux in 2010, Mérieux NutriSciences
can envisage a relevant acquisition policy and speed up its
international roll-out strategy, particularly in emerging countries
such as China, India and Brazil.

Major advances in Institut Mérieux's innovation policy

One year after it was founded, Mérieux Développement has
announced three minority holdings in innovative companies in the
health sector:

- Supersonic Imagine, a French company based in Aix-en-Provence, which
markets a new generation ultrasonic scanner, equipped with a cutting-
edge imaging technique (ultrasound elastography), thus opening up
further clinical applications in oncology, for diagnosis and
characterization of lesions (breast, thyroid, liver, prostate).
- QuantaLife, a Californian company, whose Droplet Digital(TM) PCR
technology represents major progress in the area of molecular biology,
in terms of sensitivity and precision, making it possible to offer
multiple applications in human genetics and, in the medium term, an
effective instrumentation solution for cancer and infectious disease
diagnostics
- Biom'Up, a French company based in Lyon, marketing innovative
biomaterials and implantable medical devices for surgery and developing
a new range of products (guided regeneration, adherence prevention and
hemostasis), aimed at patient comfort and safety and simplified
surgical procedures.

In the course of 2010, Mérieux Développement set up an
international cooperation and joint investment network, along with a
special partnership with the French Commissariat à l'Energie Atomique
(CEA). The purpose of this partnership is support businesses
developing high added medical value products, by means of an original
approach based on complementary expertise and close cooperation with
CEA Investissement.

The Mérieux Research Grants program steps up a gear. These grants
are awarded to projects from leading researchers and clinicians in
areas of strategic interest for Institut Mérieux: diagnostics,
therapy and nutrition. Since the program was launched in 2009, over
20 grants have been awarded to researchers from public or private
laboratories, in North America, Europe and Asia, on topics offering
strong potential for the Group. This program helps strengthen
Institut Mérieux's scientific network of experts around the world and
give bioMérieux, Transgene and Mérieux NutriSciences access to
clinical and technological advances which will be the source of new
diagnostic tests and new therapies.

Serving global public health since its inception, Institut
Mérieux is increasing its action in developing countries through the
creation of IMAccess.

With IMAccess, Institut Mérieux, in keeping with its tradition,
is seeking to place its expertise in infectious disease and its
bio-industrial experience at the service of diagnostics accessible to
the greatest number.

A 100% subsidiary of Institut Mérieux, this new company is
dedicated to the development, production and supply of rapid
diagnostic tests, for governments, international health
organizations, NGOs, etc.

These tests, complying with the most exacting international
quality standards and adapted to the frequently extreme constraints
associated with use in the field, focus on diseases which are having
a severe impact on underprivileged countries, such as AIDS, dengue,
meningitis, malaria, Leishmaniasis, etc. The first products should be
available in 2012.

IMAccess essentially relies on research and development teams
based in France, Brazil and China, along with the Group's expertise
in bioproduction and its distribution network.

In order to speed up the development of these tests and make them
accessible in terms of price, IMAccess has adopted an original social
business model, a not-for-profit company, reinvesting all its profits
in its R&D programs.

About Institut Mérieux

Institut Mérieux is committing its experience in industrial
biology to serve medicine and public health across the globe. To
fight against infectious diseases and cancers, it imagines and
develops new approaches in the fields of diagnostics, immunotherapy,
food safety and nutrition.

Through its three bio-industrial companies, bioMérieux, Transgene
and Mérieux NutriSciences , working closely with its entities devoted
to innovation (Mérieux Développement and ABL Inc.), Institut Mérieux
has the potential to offer solutions for new global public health
challenges:

bioMérieux is listed on Euronext, represents a 59% holding and is
based in Marcy l'Etoile (France). A global player in the area of in
vitro diagnostics and industrial microbiological testing, bioMérieux
employs 6300 people and generated sales of EUR1.223 billion in 2009.
It is present in 150 countries with a network of 39 subsidiaries.
http://www.biomerieux.com

Transgene is listed on Euronext, represents a 55% holding and is
based in Strasbourg (France). This biotechnology company specialized
in immunology applied to the treatment cancers and infectious
diseases employs 280 people in its programs. http://www.transgene.fr

Mérieux NutriSciences represents an 89% holding and is based in
Chicago (USA): it is a service company specialized in improving food
safety and nutrition. With a staff of 4000, Mérieux NutriSciences is,
with its three units, Silliker, Biofortis and Bioagri, now present in
16 countries,via close to 60 accredited laboratories and represents
sales totaling over $350 million. http://www.merieuxnutrisciences.com

Advanced BioScience Laboratories Inc (ABL Inc): this company is
100% owned by Institut Mérieux. Based in Washington DC (USA), it
employs over 100 people in virology R&D programs.
http://www.ablinc.com

Mérieux Développement: a company investing in the area of health,
100% owned by Institut Mérieux and based in Lyon (France).
http://www.merieux-developpement.com

Institut Mérieux employs over 10,000 people committed to global
public health and generates sales in excess of EUR1.4 billion.

http://www.institut-merieux.com

ots Originaltext: institut merieux
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Press contacts: Institut Mérieux, Anne de
Chiffreville04-72-83-48-63 anne.de.chiffreville@theraconseil.com,
Image 7, LaurenceHeilbronn 01-53-70-74-64 lheilbronn@image7.fr,
Albane de La Tour d'Artaise01-53-70-74-84 adelatour@image7.fr